Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct; 13(10):983-92.

View in: PubMed

subject areas

Abiraterone Acetate
Adult
Aged
Aged, 80 and over
Androstadienes
Castration
Double-Blind Method
Humans
Male
Middle Aged
Neoplasm Metastasis
Orchiectomy
Prostatic Neoplasms

authors with profiles

CHRISTOPHER J LOGOTHETIS